Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

Antonio Ruggiero, Cesare Colosimo, Giuseppe Barone, Vita Ridola, Riccardo Riccardi, Graziella Cefalo, Maura Massimino, Filippo Spreafico, Paolo Potepan, Massimo E. Abate, Maurizio Mascarin, Maria Luisa Garrè, Giorgio Perilongo, Enrico Madon

Risultato della ricerca: Contributo in rivistaArticolo in rivista

35 Citazioni (Scopus)

Abstract

The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.
Lingua originaleEnglish
pagine (da-a)748-753
Numero di pagine6
RivistaNeuro-Oncology
Volume16
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • medulloblastoma
  • phase II trial
  • temozolomide

Fingerprint Entra nei temi di ricerca di 'Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial'. Insieme formano una fingerprint unica.

Cita questo